BA
ALNY icon

BlackRock Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

BlackRock Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.64M Sell
43,922
-235,204
-84% -$9.85M ﹤0.01% 1601
2016
Q3 		$18.9M Sell
279,126
-93,542
-25% -$6.6M 0.02% 557
2016
Q2 		$20.7M Buy
372,668
+78,149
+27% +$4.92M 0.02% 520
2016
Q1 		$18.5M Buy
294,519
+114,990
+64% +$7.65M 0.02% 563
2015
Q4 		$16.9M Buy
179,529
+13,612
+8% +$1.26M 0.02% 606
2015
Q3 		$13.3M Buy
165,917
+6,158
+4% +$684K 0.01% 661
2015
Q2 		$19.1M Buy
159,759
+13,849
+9% +$1.66M 0.02% 536
2015
Q1 		$15.2M Buy
145,910
+136,178
+1,399% +$13.8M 0.02% 653
2014
Q4 		$944K Hold
9,732
– – ﹤0.01% 1534
2014
Q3 		$760K Sell
9,732
-32,035
-77% -$2.07M ﹤0.01% 1629
2014
Q2 		$2.64M Sell
41,767
-49,435
-54% -$2.94M ﹤0.01% 1102
2014
Q1 		$6.12M Buy
91,202
+54,503
+149% +$4.22M 0.01% 923
2013
Q4 		$2.36M Sell
36,699
-1,059,905
-97% -$63.2M ﹤0.01% 1136
2013
Q3 		$70.2M Sell
1,096,604
-73,347
-6% -$3.66M 0.07% 278
2013
Q2 		$36.3M Buy
+1,169,951
New +$31.1M 0.04% 379

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors's ALNY Position: Q4 2016 in Review

BlackRock Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 84% in Q4 2016, selling an estimated $9.85M and leaving 43,922 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #1601.

BlackRock Advisors first reported a position in ALNY in Q2 2013 and has held it in 15 quarters since. The position peaked at $70.2M in Q3 2013. 210 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

  • BlackRock Advisors held 43,922 shares of Alnylam Pharmaceuticals worth $1.64M as of Q4 2016.
  • BlackRock Advisors sold 235,204 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $9.85M.
  • Alnylam Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1601 holding.
  • BlackRock Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Alnylam Pharmaceuticals position peaked at $70.2M in Q3 2013.
  • 210 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.